Unprecedented Advances and Persistent Challenges: Key Insights from AACR’s 2024 Cancer Progress Reports
AACR’s 2024 Cancer Progress Report and Cancer Disparities Progress Report shared insights into advances and challenges in cancer research.
Related Articles
Venetoclax-Based Therapy Is Associated With Worse Outcomes in BTK Inhibitor–Resistant, Chemo-Naive CLL
Venetoclax-based treatment was associated with poorer outcomes CLL previously treated with a BTK inhibitor and naive to chemotherapy.
CPX-351 vs FLAG-Ida: Post-hoc subgroup analysis of the UK NCRI AML19 trial
During the 66th ASH Annual Meeting and Exposition, Mehta P. presented results from a post-hoc analysis of the UK NCRI AML19 trial evaluating the efficacy…
A pilot study investigating a shorter duration of isatuximab infusion in patients with myeloma
Enrique Ocio, MD, PhD, Marquis of Valdecilla University Hospital, Santander, Spain, comments on a pilot study within a larger Phase Ib study (NCT02513186) of isatuximab,…
The Epigenetic Hallmarks of Cancer
Abstract. Cancer is a complex disease in which several molecular and cellular pathways converge to foster the tumoral phenotype. Notably, in the latest iteration of…
Experts Highlight Advances and Future Directions for Adjuvant Ribociclib in HR+/HER2– Breast Cancer
Experts at the 2024 San Antonio Breast Cancer Symposium discussed knowledge gaps in understanding how best to use ribociclib in treating patients with early breast…
FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease
The FDA has approved remestemcel-L-rknd for pediatric steroid-refractory acute graft-vs-host disease.
Call-for-Papers | JACC: CardioOncology
Submission Deadline: February 15, 2025 Cardio-oncology historically has focused on the cardiotoxic effects of cancer therapies; however, as our field continues to evolve, there is…
Consolidation Durvalumab Improves PFS in Unresectable Stage III NSCLC Without Progression After CRT
The PACIFIC-5 study has met its primary end point of improved PFS with consolidation durvalumab after CRT in select unresectable stage III NSCLC.
Johnson & Johnson Seeks EMA Approval for Ibrutinib Plus R-CHOP in Frontline MCL
Johnson & Johnson has submitted a type II variation application to the EMA seeking the approval of ibrutinib plus R-CHOP in ASCT-eligible frontline MCL.
Menin Inhibitor–Based Combinations Are Central to Ongoing Research in KMT2A+/NPM1+ AML
Maximilian Stahl, MD, discusses unmet needs in relapsed/refractory AML, highlighting the potential utility menin inhibitors in select populations.